Morgan Stanley upgraded PTC Therapeutics to Equal Weight from Underweight with a price target of $30, up from $28. Following the Q1 report, the timing of the company’s upcoming regulatory milestones and clinical updates remain on track, the analyst tells investors in a research note. The firm believes the risks from PTC’s negative updates in Q4 are now well-understood by investors, limiting downside risk to the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics Q1 Financial Results Conference Call
- PTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
- PTC Therapeutics backs FY24 revenue view $600M-$680B, consensus $606.63M
- PTC Therapeutics reports Q1 EPS ($1.20), consensus ($1.24)
- PTC Therapeutics submits MAA for sepiapterin in PKU to EMA
